43 related articles for article (PubMed ID: 16554879)
1. Safety Assessment of AAV2-hGDNF Administered Via Intracerebral Injection in Rats for Treatment of Parkinson's Disease.
Terse PS; Kells AP; Noker P; Wright JF; Bankiewicz KS
Int J Toxicol; 2021; 40(1):4-14. PubMed ID: 33131343
[TBL] [Abstract][Full Text] [Related]
2. Cryogel microcarriers for sustained local delivery of growth factors to the brain.
Hakami A; Narasimhan K; Comini G; Thiele J; Werner C; Dowd E; Newland B
J Control Release; 2024 May; 369():404-419. PubMed ID: 38508528
[TBL] [Abstract][Full Text] [Related]
3. Adult human olfactory epithelial-derived progenitors: a potential autologous source for cell-based treatment for Parkinson's disease.
Wang M; Lu C; Roisen F
Stem Cells Transl Med; 2012 Jun; 1(6):492-502. PubMed ID: 23197853
[TBL] [Abstract][Full Text] [Related]
4. Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
Andereggen L; Meyer M; Guzman R; Ducray AD; Widmer HR
Brain Res; 2009 Jun; 1276():39-49. PubMed ID: 19389387
[TBL] [Abstract][Full Text] [Related]
5. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D
Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043
[TBL] [Abstract][Full Text] [Related]
6. Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra.
Nosheny RL; Bachis A; Aden SA; De Bernardi MA; Mocchetti I
J Neurobiol; 2006 Oct; 66(12):1311-21. PubMed ID: 16967504
[TBL] [Abstract][Full Text] [Related]
7. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
Winkler C; Georgievska B; Carlsson T; Lacar B; Kirik D
Neuroscience; 2006 Aug; 141(1):521-31. PubMed ID: 16697115
[TBL] [Abstract][Full Text] [Related]
8. [Preservation of brain cells in Parkinson disease].
Aasly JO
Tidsskr Nor Laegeforen; 2006 Mar; 126(7):894. PubMed ID: 16554876
[No Abstract] [Full Text] [Related]
9. [Growth factors as neuroprotective treatment in Parkinson disease?].
Torp R; Singh PB; Sørensen DR; Dietrichs E; Hirschberg H
Tidsskr Nor Laegeforen; 2006 Mar; 126(7):899-901. PubMed ID: 16554879
[TBL] [Abstract][Full Text] [Related]
10. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease.
Björklund A; Rosenblad C; Winkler C; Kirik D
Neurobiol Dis; 1997; 4(3-4):186-200. PubMed ID: 9361295
[TBL] [Abstract][Full Text] [Related]
11. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
Lindvall O; Wahlberg LU
Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
[TBL] [Abstract][Full Text] [Related]
12. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease.
Kordower JH
Ann Neurol; 2003; 53 Suppl 3():S120-32; discussion S132-4. PubMed ID: 12666104
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
